Shots:
- Alumis and ACELYRIN have amended their 2025 merger agreement, which originally granted ACELYRIN stockholders 0.4274 Alumis shares/share, giving them a 45% stake in the combined company
- As per the amendment, ACELYRIN stockholders will receive 0.4814 Alumis shares/share, allowing them to own 48% of the combined entity on a fully diluted basis; closing expected in Q2’25
- As of Dec 31, 2024, Alumis & ACELYRIN had a pro forma total of ~$737M to fund data readouts across clinical trials incl. lonigutamab & operations into 2027
Ref: Alumis | Image: Alumis & ACELYRIN
Related News:- Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
